Abstract
Postmenopausal osteoporosis is an age related skeletal metabolic disorder that affects most elderly women worldwide owing to the loss of estrogen activity, increase in bone turnover rate and circulating level of bone turnover markers. Although osteocalcin, bone specific alkaline phosphatase, and pro-collagen type I N- and C-terminal pro-peptides are considered as the most sensitive markers of bone formation however, they suffer some limitations. Consequently, periostin, sclerostin and dickkopf-1 protein (Dkk-1) are emerging diagnosis markers of bone pathologies and monitoring therapeutic interventions and management of postmenopausal osteoporosis. These markers serve as effective tools for diagnosis of bone disorders, predict reduction in fracture risk, reflect metabolic effect of drugs during bone remodeling and could be used to establish the lowest dose that elicit the required change in bone mineral density. Biological variability from different sources including controllable and uncontrollable factors could serve as the major limitations of these established markers of bone formation (BFMs). This review, therefore focus on the therapeutic applications of selected bone turnover markers for early diagnosis of postmenopausal osteoporosis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Science for Global Sustainability
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
